A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily t...

Source: BMC Neurology - October 29, 2018 Category: Neurology Authors: A. G. Vakrakou, D. Tzanetakos, S. Valsami, E. Grigoriou, K. Psarra, J. Tzartos, M. Anagnostouli, E. Andreadou, M. E. Evangelopoulos, G. Koutsis, C. Chrysovitsanou, E. Gialafos, A. Dimitrakopoulos, L. Stefanis and C. Kilidireas Tags: Case report Source Type: research